SynthesisTargeted oncology2014
Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.
Synthesis in Targeted oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.Ontario health technology assessment series · 2024Article
- The predictive value of [EJNMMI research · 2023Article
- Association Analysis of Maximum Standardized Uptake Values Based onJournal of personalized medicine · 2023Article
- Article
- A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients.Diagnostics (Basel, Switzerland) · 2020Article
- The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.Cellular and molecular life sciences : CMLS · 2019Article
- Article
- Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis.Current respiratory medicine reviews · 2018Review
- Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.Medicine · 2018Article
- The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing.Molecular diagnosis & therapy · 2017Review
- Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.Oncotarget · 2017Article
- Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Oncotarget · 2017Review
- EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.Canadian respiratory journal · 2016Article
- Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015Article
- Targeted treatment of mutatedLung Cancer (Auckland, N.Z.) · 2014Review
- Liquid biopsy for T790M mutation detection: A ray of hope?Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer tissues is necessary for effective treatment with EGFR tyrosine kinase inhibitors. However, tumor tissues may not be available in all situations. Studies have evaluated the potential use of serum or plasma for detecting the EGFR mutation status, but the results have been inconclusive. Here, a meta-analysis was performed to determine whether blood samples could serve as substitutes for tissue specimens in detecting the EGFR mutation status. Databases, including PubMed and Embase, were searched for relevant studies published from 2005 to 2013 that included true-positive, false-positive, true-negative, and false-negative values of the EGFR mutation status of the blood compared with tissue specimens. Summary receiver operating characteristic curves were developed to explore the threshold effect. Spearman's correlation coefficient was calculated to analyze the heterogeneity between studies. Pooled sensitivity and specificity were evaluated using Meta-DiSc version 1.4. Thirteen articles involving 1,591 cases were enrolled, with a pooled sensitivity and specificity of 64.5 % (95 % CI = 0.605-0.683) and 88.5 % (95 % CI = 0.863-0.904), respectively. Heterogeneity among the studies was caused by factors other than threshold effect. The findings were influenced by test method (p = 0.0354). Blood samples had a high specificity and relatively low sensitivity for detecting EGFR mutations compared to tumor tissues. The results of this meta-analysis suggest that peripheral blood is insufficient as a substitute for tumor tissues in detecting EGFR mutations in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.